ANGLE to highlight the potential of its technology in breast and lung cancers at upcoming virtual meetings

ANGLE PLC (LON:AGL) said promising data highlighting the potential of its liquid biopsy in breast and lung cancers will be released in two posters at virtual meetings taking place this week and next month. The first assesses the potential of the Parsortix system to identify pithelial and mesenchymal circulating tumour cells. Competing systems sometimes miss ‘clinically relevant’ cells. The second poster looks at the ability of the ANGLE technology to identify PD-L1 expression, which could offer some big clues as to which patients might benefit from the new breed of immunotherapy drugs. Importantly, Parsortix could also provide a method of monitoring patients on these therapies. The posters are being published to coincide with the American Association for Cancer Research Conference (AACR) 2021. This is being held as virtual meetings on April 10-15, and on May 17-21. In the update, ANGLE chief executive Andrew Newland said the business was in  “advanced discussions” with potential customers “for the deployment of the Parsortix system in cancer drug clinical trials”. This follows the launch of clinical services laboratories in the UK and United States. For more information click here